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Abstract: In this study we report the synthesis of C5/C6-fused uridine phosphonates that 
are structurally related to earlier reported allosteric P2Y2 receptor ligands. A silyl-Hilbert-
Johnson reaction of six quinazoline-2,4-(1H,3H)-dione-like base moieties with a suitable 
ribofuranosephosphonate afforded the desired analogues after full deprotection. In contrast 
to the parent 5-(4-fluoropheny)uridine phosphonate, the present extended-base uridine 
phosphonates essentially failed to modulate the P2Y2 receptor. 
Keywords: nucleoside phosphonates; extended uridine; P2Y2 receptor 
 
1. Introduction 
Amongst the many physiological functions of nucleotides, their capacity to mediate signal 
transmission via cell-surface receptors was discovered in 1929 [1]. Purinergic receptors are subdivided 
into two families: metabotropic P2Y receptors (P2YRs) and fast acting P2X ion channels [2]. The P2X 
receptors generally respond to the native agonist ATP, whereas P2YRs can be activated by ATP, UTP, 
UDP and UDP-glucose. The P2YRs family consist of eight members, which can be divided in two 
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subgroups based on receptor structure and second messenger system: P2Y1,2,4,6,11 and P2Y12,13,14 [3]. 
Ligand preferences of the eight P2YRs have been well established: P2Y1 (ADP), P2Y2 (UTP=ATP), 
P2Y4 (UTP), P2Y6 (UDP), P2Y11 (ATP, NAD+), P2Y12 (ADP), P2Y13 (ADP), and P2Y14 (UDP, UDP 
nucleotide sugars) [4]. 
The P2Y2 receptor (P2Y2R) is responsible for many physiological functions and therefore attracts 
considerable attention for developing therapeutics. For example, the P2Y2R agonist diquafosol, which 
stimulates the secretion of chloride and water by epithelial cells, is approved in Japan for treatment of 
dry eye disease [5]. P2Y2R activation protects cardiomyocytes from hypoxia in vitro and reduces post-
ischemic myocardial damage in vivo [2]. Furthermore, the P2Y2R is a promising target for the 
treatment of neurodegenerative diseases, including Alzheimer’s disease [6]. Recently, ATP activation 
of the P2Y2R was also shown to retard bone mineralization [1]. 
The development of selective P2Y2R agonists and antagonists is a challenging task. Introduction of 
a 2'-amino and a 2-thio modification in UTP afforded analogue 1 (Figure 1) with enhanced potency 
and selectivity (versus P2Y4R) [7]. Unfortunately, most P2Y2R agonists contain a polyphosphate 
group, which is easily hydrolyzed by ecto-nucleotidases [4]. We recently reported a series of stable  
5-substituted uridine phosphonate analogues, some of which (e.g., 2, Figure 1) showed promising 
allosteric partial agonistic activity at P2Y2R [8]. Given the interesting profile of the 5-aryluridine 
analogues we envisaged modifying this nucleobase to a more rigid structure as a way to potentially 
enhance affinity for the P2Y2R. In this light we opted for a ring transformation from a 5-aryluracil to a 
quinazoline-2,4-dione motif, analogous to the biphenyl-naphthalene ring transformations often 
encountered in medicinal chemistry [9]. The first series of 5,6-annulated uridine analogues were based 
on the aromatic Topliss-scheme [6-H (3a), Cl (3c), OMe (3e) and Me (3d)] [10]. Additionally the  
6-fluorine derivative 3b was chosen based on the notable potency of parent compound 2 which bears a 
fluorine atom. Finally two nucleobases involving substitution of the benzene ring for a thiophene (3f) 
or a naphthalene core (3g) were included to gauge the effect of bioisosteric replacement or ring 
expansion of the nucleobase on the affinity for the P2Y2R. 
Figure 1. Structure of UTP, the selective P2Y2 agonist 1, the allosteric partial agonist 2 
and the target nucleoside phosphonates 3. 
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2. Results and Discussion 
2.1. Synthesis  
To gain access to the target C5/C6-fused uridine phosphonates we first prepared the required “base” 
moieties 4a–g by condensation of the appropriate ortho-amino aromatic carboxylic acids and urea at 
high temperature [11–13].  
The synthesis of the appropriate glycosyl donor started from the known diol 6, which was obtained 
in two steps from the commercial 1,2:5,6-O-diisopropylidene-α-D-allofuranose (5) following a known 
procedure (Scheme 1) [14]. Cleavage of the resulting vicinal diol with sodium periodate gave the 
aldehyde [15], which was used without purification in the subsequent Wittig-type reaction. During 
formation of the diethylvinylphosphonate 7, C-4 may be prone to epimerization, which could be 
limited by performing the reaction at lower temperature. The yield for the conversion of 6 to 7 was 
significantly increased by using dichloromethane instead of ethanol for the periodate reaction. 
Hydrogenation with 10% Pd/C at atmospheric pressure allowed to simultaneous reduction of the 
double bond and removal of the benzyl group. One-pot deprotection of the isopropylidene group and 
acetylation of 8 afforded 9 (with an anomeric ratio of ca. 4:1 in favor of the  anomer), which was 
used in a silyl-Hilbert-Johnson reaction with the silylated benzo- or thieno[3,2-d]pyrimidine-2,4-
diones to give compounds 10a–g [16]. When HMDS was used as the silylating agent, careful removal 
of the silylating agents prior to the addition of the base and trimethylsilyltrifluoromethane sulfonate 
was required. Hence, the use of BSTFA for in situ silylation was preferred, despite the fact that it 
generally gave lower yields. Final deacetylation, followed by treatment with TMSBr/DCM afforded 
the desired nucleoside phosphonate analogues 3a–g. 
Scheme 1. Synthesis of the Target Extended Uridine-5'-methylenephosphonates 3a–g. 
 
Reagents and conditions: (a) (i) NaIO4, DCM, H2O, rt; (ii) tetraethyl methylenediphosphonate, NaH, THF,  
0 °C → rt; (b) H2, 10% Pd/C, rt; (c) (i) 60% AcOH, 85 °C, overnight; (ii) Ac2O, pyridine, overnight; (d) (i) 
BSTFA, ACN, 65 °C, 2 h; (ii) TMSOTf, CH3CN; (iii) NaOMe/MeOH, rt; (e) TMSBr, DCM, rt. 
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2.2. Pharmacological Evaluation 
Agonist and antagonist activities of the C5/C6-fused uridine phosphonates at the P2Y2 receptor 
were determined measuring PLC-dependent phosphoinositide hydrolysis in 1321N1 human 
astrocytoma cells stably expressing the human P2Y2 receptor (1321N1-P2Y2 cells) [17,18] (Figure 2). 
Compared to compound 2, the current extended uridine phosphonates were found to stimulate the 
P2Y2 receptor to a lesser extent, indicating that rigidifying the base moiety is unfavorable for binding 
to a presumed allosteric binding site. It can be concluded that structural flexibility of the 5-substituent 
of the earlier discovered series of allosteric P2Y2 agonists is crucial for allosteric agonist activity.  
Figure 2. Inositol phosphate production in 1321N1 cells stably expressing the human P2Y2 
receptor. After labeling with [3H]myo-inositol overnight, the cells were treated with 
agonists for 30 min at 37 °C in the presence of 10 mM LiCl, and inositol phosphate 
accumulation was quantified. The concentration of all phosphonate analagues was 30 μM 
and of UTP was 3 μM. The data are presented as the mean ± S.E.M. and are representative 
of results obtained in three separate experiments.  
 
The possibility that the modified uridine 5'-phosphonate analogues could inhibit the effect of UTP 
by displacing it from the orthosteric site was examined by assessing their capacity at high 
concentrations to inhibit the effect of a near-maximal concentration of UTP (Figure 3). None of the 
phosphonate analogues gave an inhibitory effect on the action of UTP. 
  
Agonist activity
Bu
ffe
r
UT
P
SV
C 
33
3 3a 3b 3c 3d 3e 3f 3g
0
20
40
60
80
100
120
%
 o
f m
ax
im
al
 re
sp
on
se
Molecules 2014, 19 4317 
 
 
Figure 3. Effect of high concentrations of phosphonate analogues 3a–g on the P2Y2 
receptor-mediated activity of UTP. The effects of 30 μM concentrations of the indicated 
phosphonates were tested in the presence of 100 μM UTP in 1321N1-P2Y2 cells. 
 
3. Experimental  
3.1. General Methods and Materials 
All reagents were from standard commercial sources and of analytic grade. All reaction were 
performed under argon atmosphere except specified otherwise. Dry solvents were directly acquired 
from commercial sources. Precoated Merck Silica Gel F254 plates were used for TLC. Spots were 
examined under ultraviolet light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. 
Column chromatography was performed on silica gel (200–400 mm, 60 Å). 1H, 13C, and 31P-NMR 
spectra were recorded in CDCl3, DMSO-d6, or D2O on a Varian Mercury 300 MHz spectrometer 
(Varian, Palo Alto, CA, USA). Chemical shifts are given in parts per million (ppm δ), δ relative to 
residual solvent peak or TMS for 1H and 13C and to external D3PO4 for 31P. Structural assignment was 
confirmed with COSY, HSQC and HMBC. Exact mass measurements were performed on a LCT 
Premier XE orthogonal time-of flight spectrometer with API-ES source (Waters, Zellik, Belgium) 
Waters LCT Premier XETM Time of flight (TOF) instrument. Samples were infused in a CH3CN/H2O 
(1:1) mixture at 10 mL/min. 
Diethyl ((E)-2-((3aR,5R,6R,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-
vinyl)phosphonate (7): NaIO4 (0.52 g, 2.22 mmol) was added to a stirred solution of compound 6 in 
CH2Cl2 (15 mL) and H2O (10 mL) and the reaction mixture was stirred for 0.5 h at rt. The mixture was 
then filtrated and the filtrate was extracted with CH2Cl2. The combined organic layers were concentrated  
in vacuo to give the crude aldehyde, which was used in the next step without further purification. To a 
stirred suspension of NaH (0.31 g, 7.81 mmol) in dry THF (10 mL) was added tetraethyl methylene 
bisphosphonate (1.41 g, 4.88 mmol) under argon. After 0.5 h the mixture was cooled in an ice bath and 
a solution of the crude aldehyde in THF (10 mL) was added. The reaction mixture was allowed to 
warm to rt and stirred overnight. The crude mixture was diluted with water (20 mL) and extracted with 
ethyl acetate (3 × 20 mL). The combined organic layers were dried (Na2SO4) and concentrated  
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in vacuo. Silica gel column chromatography (CH2Cl2/MeOH 97:3) afforded compound 7 as a colorless 
oil (0.77 g, 84.2%). 1H-NMR (300 MHz, CDCl3) δ: 1.28–1.35 (m, 6H, OCH2CH3), 1.36, 1.60 (2s, 6H, 
C(CH3)2), 3.53 (dd, J = 9.2, 4.2 Hz, 1H, H-3'), 3.98–4.16 (m, 4H, OCH2CH3), 4.55–4.66 (m, 3H,  
H-2',H-4', OCH2Ph), 4.70–4.77 (m, 1H, OCH2Ph), 5.77 (d, J = 3.8 Hz, 1H, H-1'), 5.96–6.12 (m, 1H, 
CH=CH), 6.74–6.90 (m, 1H, CH=CH), 7.28–7.42 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 16.47, 
16.56 (OCH2CH3), 26.63, 26.93 (C(CH3)2), 61.97 (t, J = 4.7 Hz, OCH2CH3), 72.57 (OCH2Ph), 77.68 
(d, J = 9.4 Hz, C-4'), 78.04 (C-2'), 81.93 (d, J = 1.7 Hz, C-3'), 104.15 (C-1'), 113.48 (C(CH3)2), 118.45 
(d, J = 186.0 Hz, C-6'), 128.18 , 128.30, 128.68, 137.19 (Ph), 148.00 (d, J = 6.1 Hz, C-5'). 31P-NMR 
(CDCl3) δ: 17.49. HRMS (ESI): Calculated for C20H30O7P [(M+H)+], 413.1724; found, 413.1754. 
Diethyl (2-((3aR,5R,6R,6aR)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)ethyl) 
phosphonate (8): To a solution of compound 7 (0.91 g, 2.22 mmol) in MeOH was added 10% Pd/C  
(0.5 g). The reaction mixture was stirred for 2 h under hydrogen atmosphere at rt and filtered. The 
filtrate was evaporated under vacuum and the residue purified by silica gel column chromatography 
(CH2Cl2/MeOH 97:3) to yield compound 8 as a colorless oil (0.58 g, 81.5%). 1H-NMR (300 MHz, 
CDCl3) δ: 1.29–1.35 (m, 6H, OCH2CH3), 1.36, 1.56 (2s, 6H, OC(CH3)2), 1.79–2.12 (m, 4H, H-5'a, H-5'b, 
H-6'a and H-6'b), 3.62 (ddd, J = 10.3, 8.7, 5.3 Hz, 1H, H-3'), 3.77 (ddd, J = 8.6, 6.7, 4.2 Hz, 1H, H-4'), 
4.0–4.23 (m, 4H, OCH2CH3), 4.56 (dd, J = 5.0, 4.1 Hz, 1H, H-2'), 5.77 (d, J = 4.1 Hz, 1H, H-1);  
13C-NMR (75 MHz, CDCl3) δ: 16.43, 16.50 (OCH2CH3), 20.61 (d, J = 141.7 Hz, C-6'), 24.99 (d,  
J = 5.0 Hz, C-5'), 26.40, 26.52 (C(CH3)2), 61.67 (d, J = 6.63 Hz, OCH2CH3), 75.55 (C-3'), 78.76  
(C-2'), 79.49 (d, J = 15.8 Hz, C-4'), 103.65 (C-1'), 112.52 (C(CH3)2); 31P-NMR (CDCl3) δ: 31.66. 
HRMS (ESI): calculated for C13H26O7P [(M+H)+], 325.1411; found, 325.1429. 
(3R,4R,5R)-5-(2-(Diethoxyphosphoryl)ethyl)tetrahydrofuran-2,3,4-triyl triacetate (9): A solution of 
compound 8 (0.45 g, 1.38 mmol) and 60% AcOH (10 mL) was heated at 80 °C under argon for 16 h. 
When the starting material was consumed completely, the reaction mixture was evaporated in vacuo 
and co-evaporated twice with AcCN. The residue was dissolved in dry pyridine (12 mL) at 0 °C under 
argon followed by dropwise addition of acetic anhydride (1.56 mL, 16.52 mmol). The reaction mixture 
was slowly warmed to rt and stirred overnight. Then it was concentrated and co-evaporated with 
toluene. The residue was purified by silica gel column chromatography (CH2Cl2/MeOH 95:5) to give 9 
(0.47 g, 83.2%) as a low melting solid (α:β anomeric ratio = 41:9). α anomer: 1H-NMR (300 MHz, 
CDCl3) δ: 1.22–1.30 (m, 6H, OCH2CH3), 1.63–1.94 (m, 4H, H-5'a, H-5′b, H-6'a and H-6'b), 1.99, 2.02, 
2.04 (s, 9H, 3COCH3), 3.96–4.08 (m, 4H, OCH2CH3), 4.08–4.17 (m, 1H, H-4'), 5.09 (dd, J = 7.0, 4.9 Hz, 
1H, H-3'), 5.25 (d, J = 4.9 Hz, 1H, H-2'), 6.06 (s, 1H, H-1'). 13C-NMR (75 MHz, CDCl3) δ: 16.49, 
16.57 (OCH2CH3), 20.58, 20.60 (COCH3), 21.80 (d, J = 143.3 Hz, C-6'), 21.15 (COCH3), 27.27 (d,  
J = 4.4 Hz, C-5'), 61.73, 61.82 (OCH2CH3), 73.27 (C-3'), 74.65 (C-2'), 81.27 (d, J = 18.2 Hz, C-4'), 
98.24 (C-1'), 169.19, 169.52, 169.87 (CO). 31P-NMR (CDCl3) δ: 30.82. β anomer: 1H-NMR (300 MHz, 
CDCl3) δ: 1.32 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.72–1.98 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 2.06, 
2.10, 2.11 (s, 9H, 3 COCH3), 4.01–4.17 (m, 4H, OCH2CH3), 4.20–4.29 (m, 1H, H-4'), 5.02 (dd,  
J = 6.8, 3.7 Hz, 1H, H-3'), 5.19 (dd, J = 6.8, 4.6 Hz, 1H, H-2'), 6.36 (d, J = 4.6 Hz, 1H, H-1').  
13C-NMR (75 MHz, CDCl3) δ: 16.54, 16.62 (OCH2CH3), 20.43, 20.76, 21.17 (COCH3), 21.81 (d,  
J = 141.83 Hz, C-6'), 26.72 (d, J = 4.4 Hz, C-5'), 61.81, 61.88 (OCH2CH3), 69.95 (C-2′), 72.02 (C-3'), 
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83.06 (d, J = 17.1 Hz, C-4'), 93.95 (C-1'), 169.46, 169.80, 170.17 (CH3CO). 31P-NMR (CDCl3) δ: 
30.57. ESI-HRMS for [C16H27O10P+H]+ calcd, 411.1420; found, 411.1436. HRMS (ESI): calculated 
for C16H28O10P [(M+H)+], 411.1415; found 411.1436. 
3.2. General Procedures for the Silyl-Hilbert-Johnson Reaction to Synthesize Products 10a to 10g 
Method 1: To a suspension of the appropriate quinazoline-2,4-(1H,3H)-dione (1.5 eq.) in dry 
acetonitrile (50 eq.) was added BSTFA (4 eq.) under argon. The solution was heated at 65 °C for 2 h. 
After cooling, a solution of triacetate 9 (1 eq.) in dry acetonitrile (50 eq.) and trimethylsilyl triflate (1.5 eq.) 
were added. The solution was stirred for 2 h at rt. The reaction was quenched with saturated aqueous 
NaHCO3 (50 mL for 1 mmol triacetate 9) and extracted with dichloromethane (50 mL for 1 mmol 
triacetate 9). The combined organic layer was washed with saturated aqueous NaHCO3 (3 × 50 mL for 
1 mmol triacetate 9), dried over anhydrous MgSO4 and evaporated. The crude mixture was dissolved 
in MeOH (50 eq.) and 5.4 N sodium methoxide (8 eq.) in MeOH was added dropwise. After 1 h, the 
mixture was neutralized with acetic acid (10 eq.) and evaporated. Purification of the residue by  
silica-gel column chromatography (CH2Cl2/MeOH 97:395:5) gave the pure product as a white foam.  
Method 2: To a suspension of appropriate quinazoline-2,4-(1H,3H)-dione (1.5 eq.) in hexamethyl-
disilazane (50 eq.) was added trimethylsilyl chloride (0.7 eq.) and pyridine (10 eq.) under argon. The 
mixture was stirred at 130 °C overnight. The reaction mixture was evaporated to dryness under high 
vacuum. To the obtained residue a solution of triacetate 9 (1 eq.) in dry acetonitrile (50 eq.) was added 
under nitrogen followed by trimethylsilyl triflate (1.5 eq.). The solution was stirred for 2 h at rt. and the 
work up was similar as described in method 1. 
Diethyl-(2-((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxy tetrahydrofuran-2-
yl)ethyl)phosphonate (10a): Following Method 1 reaction between 9 (0.47 g, 1.14 mmol) and 4a (0.28 g, 
1.71 mmol) yielded compound 10a (0.22 g, 50%). 1H-NMR (300 MHz, CDCl3) δ: 1.27 (dt, J = 18.3, 
7.1 Hz, 6H, OCH2CH3), 1.79–2.15 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 2.15–2.36 (m), 4.45 (br s), 
4.97 (br s, 2OH, NH), 3.88–3.97 (m, 1H, H-4'), 3.97–4.15 (m, 4H, OCH2CH3), 4.59 (t, J = 6.7 Hz, 
1H, H-3'), 4.80–4.89 (m, 1H, H-2'), 5.96 (d, J = 2.0 Hz, 1H, H-1'), 7.19–7.27 (m, 1H), 7.45 (d,  
J = 8.7 Hz, 1H), 7.59–7.67 (m, 1H), 8.14 (d, J = 7.7 Hz, 1H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 
15.99–16.20 (m, OCH2CH3), 20.69 (d, J = 141.8 Hz, C-6'), 25.02 (d, J = 4.4 Hz, C-5'), 61.66 (dd,  
J = 12.2, 6.6 Hz, OCH2CH3), 71.95 (C-3'), 72.50 (C-2'), 82.32 (d, J = 17.7 Hz, C-4'), 91.68 (C-1'), 
114.27,115.92, 123.41, 128.37, 135.12 and 140.98 (Ph), 149.74 (C-2), 162.04 (C-4). 31P-NMR 
(CDCl3) δ: 32.08. HRMS (ESI): calculated for C18H24N2O8P [(M–H)−], 427.1276; found, 427.1284. 
Diethyl-(2-((2R,3S,4R,5R)-5-(6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxy-
tetrahydrofuran-2-yl)ethyl)phosphonate (10b): Following Method 2 reaction between 9 (0.34 g,  
0.84 mmol) and 4b (0.18 g, 1.01 mmol) yielded compound 10b (133.3 mg, 61.3%). 1H-NMR (300 MHz, 
CDCl3) δ: 1.29 (dt, J = 17.9, 7.1 Hz, 6H, OCH2CH3), 1.80–2.15 (m, 4H, H-5'a, H-5'b, H-6'a and  
H-6'b), 3.89–3.98 (m, 1H, H-4'), 3.98–4.16 (m, 4H, OCH2CH3), 4.29, 5.01, 10.31 (br s, 2OH, NH), 
4.60 (t, J = 6.2 Hz, 1H, H-3'), 4.83 (dd, J = 6.2, 2.3 Hz, 1H, H-2'), 5.90 (d, J = 2.6 Hz, 1H, H-1'), 
7.33–7.42 (m, 1H, Ph), 7.43–7.50 (m, 1H, Ph), 7.78–7.85 (m,1H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 
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16.57 (d, J = 5.53 Hz, OCH2CH3), 21.14 (d, J = 140.1 Hz, C-6'), 25.52 (t, J = 5.3 Hz, C-5'), 62.14 (dd, 
J = 13.82, 6.6 Hz, OCH2CH3), 72.36 (C-3'), 73.01 (C-2'), 82.87 (d, J = 17.1 Hz, C-4'), 92.40 (C-1'), 
114.10–114.57 (m, Ph), 116.86 (d, J = 7.2 Hz, Ph), 117.68–117.98 (m, Ph), 122.86–123.38 (m, Ph), 
137.76 (Ph), 149.83 (C-2), 156.99–160.41 (m, Ph), 161.39 (C-4). 31P-NMR (CDCl3) δ: 32.71. HRMS 
(ESI): Calculated for C18H23FN2O8P [(M–H)−], 445.1182; found, 445.1188. 
Diethyl-(2-((2R,3S,4R,5R)-5-(6-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxytetra- 
hydrofuran-2-yl)ethyl)phosphonate (10c): The reaction between 9 (0.34 g, 0.84 mmol) and 4c (0.25 g, 
1.26 mmol) as described for method 1 to yield compound 10c (0.18 g, 45.1%). 1H-NMR (300 MHz, 
CDCl3) δ:1.28 (dt, J = 16.69, 7.03 Hz, 6H, OCH2CH3), 1.79–2.14 (m, 4H, H-5'a, H-5'b, H-6'a and  
H-6'b), 3.92 (q, J = 5.8 Hz, 1H, H-4'), 3.97–4.15 (m, 4H, OCH2CH3), 4.55 (t, J = 6.7 Hz, 1H, H-3'), 
4.85 (dd, J = 6.15, 2.3 Hz, 1H, H-2'), 4.96, 10.49 (br s OH, NH), 5.89 (d, J = 2.6 Hz, 1H, H-1'), 7.40 
(d, J = 9.4 Hz, 1H, Ph), 7.57 (dd, J = 9.1, 2.6 Hz, 1H, Ph), 8.04 (d, J = 2.3 Hz, 1H, Ph). 13C-NMR  
(75 MHz, CDCl3) δ: 16.44–16.63 (m, OCH2CH3), 21.13 (d, J = 141.0 Hz, C-6'), 25.48 (d, J = 4.4 Hz, 
C-5'), 62.13 (dd, J = 11.6, 6.6 Hz, OCH2CH3), 72.42 (C-3'), 72.80 (C-2'), 82.84 (d, J = 17.1 Hz, C-4'), 
92.25 (C-1'), 116.51, 117.55, 128.08, 129.76, 135.46 and 139.87 (Ph), 149.85 (C-2), 161.33 (C-4).  
31P-NMR (CDCl3) δ: 32.68. HRMS (ESI): calculated for C18H23ClN2O8P [(M−H)−], 461.0886;  
found, 461.0899. 
Diethyl-(2-((2R,3S,4R,5R)-5-(6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxytetra- 
hydrofuran-2-yl)ethyl)phosphonate (10d): The reaction between 9 (0.25 g, 0.61 mmol) and 4d (0.16 g, 
0.91 mmol) as described for method 1 to yield compound 10d (125.2 mg, 46.5%). 1H-NMR (300 MHz, 
CDCl3) δ:1.28 (dt, J = 19.0, 7.1 Hz, 6H, OCH2CH3), 1.81–2.18 (m, 4H, H-5'a, H-5′b, H-6'a and H-6'b), 
2.37 (s, 3H, CH3), 3.88–3.97 (m, 1H, H-4'), 3.97–4.16 (m, 4H, OCH2CH3), 4.28 (br s, 1H, OH),  
4.56–4.68 (m, 1H, H-3'), 4.80–4.88 (m, 1H, H-2'), 4.98 (d, J = 5.0 Hz, 1H, OH), 5.94 (d, J = 2.3 Hz, 
1H, H-1'), 7.34 (d, J = 8.8 Hz, 1H, Ph), 7.40–7.48 (m, 1H, Ph), 7.94 (s, 1H, Ph), 10.28 (s, 1H, NH).  
13C-NMR (75 MHz, CDCl3) δ: 15.78–16.15 (m, OCH2CH3), 20.51 (d, J = 141.0 Hz, C-6'), 19.95 (CH3), 
24.83 (d, J = 4.4 Hz, C-5'), 61.26–61.77 (m, OCH2CH3), 71.76 (C-3'), 72.55 (C-2'), 82.18 (d, J = 17.1 Hz, 
C-4'), 91.52 (C-1'), 113.98, 115.56, 127.99, 133.17, 135.95 and 138.69 (Ph), 149.56 (C-2), 161.96  
(C-4). 31P-NMR (CDCl3) δ: 32.84. HRMS (ESI): calculated for C19H26N2O8P [(M−H)−], 441.1432; 
found, 441.1427. 
Diethyl-(2-((2R,3S,4R,5R)-5-(6-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxy- 
tetrahydrofuran-2-yl)ethyl)phosphonate (10e): The reaction between 9 (0.25 g, 0.61 mmol) and 4e 
(0.18 g, 0.91 mmol) as described for method 1 to yield compound 10e (122.7 mg, 44.0%).  
1H-NMR (300 MHz, CDCl3) δ:1.21–1.35 (m, 6H, OCH2CH3), 1.79–2.17 (m, 4H, H-5'a, H-5'b, H-6'a 
and H-6'b), 3.86 (s, 3H, OCH3), 3.89–3.97 (m, 1H, H-4'), 3.98–4.15 (m, 4H, OCH2CH3), 4.63 (t,  
J = 6.7 Hz, 1H, H-3'), 4.85 (dd, J = 6.0, 2.5 Hz, 1H, H-2'), 5.04 (br s, OH), 5.92 (d, J = 2.3 Hz, 1H,  
H-1'), 7.20–7.25 (m, 1H, Ph), 7.39 (d, J = 9.7 Hz, 1H, Ph), 7.59 (d, J = 3.2 Hz, 1H, Ph), 10.27 (br s, 
1H, NH). 13C-NMR (75 MHz, CDCl3) δ: 16.42–16.64 (m, OCH2CH3), 21.09 (d, J = 141.0 Hz, C-6'), 
25.42 (d, J = 4.4 Hz, C-5'), 56.02 (OCH3), 62.08 (dd, J = 14.9, 6.6 Hz, OCH2CH3), 72.33 (C-3'), 73.08 
(C-2'), 82.78 (d, J = 17.1 Hz, C-4'), 92.19 (C-1'), 109.63, 116.27, 117.12, 124.35 and 135.41 (Ph), 
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149.94 (C-2), 155.95 (Ph), 162.30 (C-4). 31P-NMR (CDCl3) δ: 32.82. HRMS (ESI): calculated for 
C19H26N2O9P [(M−H)−], 457.1381; found, 457.1390. 
Diethyl-(2-((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-3,4-dihydroxy- 
tetrahydrofuran-2-yl)ethyl)phosphonate (10f): The reaction between 9 (0.25 g, 0.61 mmol) and 4f 
(0.15 g, 0.91 mmol) as described for method 1 to yield compound 10f (198.8 mg, 75.2%).  
1H-NMR (300 MHz, CDCl3) δ:1.20–1.35 (m, 6H, OCH2CH3), 1.79–2.15 (m, 4H, H-5'a, H-5'b, H-6'a 
and H-6'b), 3.92 (q, J = 6.1 Hz, 1H, H-4'), 3.97–4.14 (m, 4H, OCH2CH3), 4.50 (t, J = 6.3 Hz, 2H,  
H-3', OH), 4.80 (dd, J = 5.9, 2.9 Hz, 1H, H-2'), 4.95 (br s, 1H, OH), 5.81 (d, J = 3.2 Hz, 1H, H-1'), 
7.13 (d, J = 5.3 Hz, 1H, H-6), 7.73 (d, J = 5.6 Hz, 1H, H-7), 10.33 (br s, 1H, NH). 13C-NMR (75 MHz, 
CDCl3) δ: 16.43–16.62 (m, OCH2CH3), 21.15 (d, J = 141.0 Hz, C-6'), 25.54 (d, J = 4.4 Hz, C-5'), 
62.12 (dd, J = 14.4, 6.6 Hz, OCH2CH3), 72.39 (C-3'), 72.71 (C-2'), 83.14 (d, J = 17.1 Hz, C-4'), 93.87 
(C-1'), 114.38 (C-4a), 116.94 (C-6), 135.47 (C-7), 146.87 (C-7a), 151.09 (C-2), 158.53 (C-4).  
31P-NMR (CDCl3) δ: 32.63. HRMS (ESI): calculated for C16H22N2O8PS [(M−H)−], 433.0840;  
found, 433.0838. 
Diethyl-(2-((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydrobenzo[g]quinazolin-1(2H)-yl)-3,4-dihydroxytetra- 
hydrofuran-2-yl)ethyl)phosphonate (10g): The reaction between 9 (0.25 g, 0.61 mmol) and 4g (0.19 g, 
0.91 mmol) as described for method 1 to yield compound 10g (125.0 mg, 43.1%). 1H-NMR (300 MHz, 
CDCl3) δ:1.22 (t, J = 7.0 Hz, 6H, OCH2CH3), 1.77–2.07 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 3.81 
(d, J = 4.4 Hz, 1H, H-4'), 3.98 (quin, J = 7.1 Hz, 4H, 2 × OCH2CH3), 4.13–4.26 (m, 1H, H-3'), 4.65 
(br s, 1H, H-2'), 5.05 (d, J = 6.2 Hz, 1H, OH), 5.21–5.32 (m, 1H, OH), 6.11 (d, J = 4.1 Hz, 1H, H-1'), 
7.54 (t, J = 7.3 Hz, 1H, Ph), 7.66 (t, J = 7.3 Hz, 1H, Ph), 7.91 (s, 1H, Ph), 8.06 (d, J = 8.2 Hz, 1H, Ph), 
8.14 (d, J = 8.2 Hz, 1H, Ph), 8.75 (s, 1H, Ph), 11.68 (br s, 1H, NH). 13C-NMR (75 MHz, CDCl3) δ: 
16.24, 16.31 (OCH2CH3), 20.74 (d, J = 140.1 Hz, C-6'), 25.63 (d, J = 3.9 Hz, C-5'), 60.92 (dd, J = 6.1, 
2.8 Hz, OCH2CH3), 70.12 (C-2'), 72.01 (C-3'), 82.07 (d, J = 17.1 Hz, C-4'), 91.20 (C-1'), 111.46, 
116.35, 125.85, 127.59, 128.34, 129.05, 129.36, 129.52, 135.99 and 136.04 (Ph), 149.80 (C-2), 161.65 
(C-4). 31P-NMR (CDCl3) δ: 32.08. HRMS (ESI): calculated for C22H26N2O8P [(M−H)−], 477.1432; 
found, 477.1419. 
3.3. General Procedure for the Deprotection of 10a–g to 3a–g 
The appropriate phosphonic ester 10 (1 eq.) was dissolved in dry CH2Cl2 (50 eq.) and treated with 
TMSBr (20 eq.) at 0 °C under argon. After stirring overnight at rt, the mixture was quenched with 7 N 
NH3/MeOH (20 eq.) and evaporated. The residue was dissolved in H2O (15 mL for 0.1 mmol 
phosphonic ester) and washed with CH2Cl2 (3 × 10 mL for 0.1 mmol phosphonic ester). The aqueous 
layer was evaporated and purified with RP high-performance liquid chromatography (HPLC, 
Phenomenex Luna C-18, H2O/0.1% HCOOH in CH3CN, 90:10→0:100 in 23 min, flow 17.5 mL/min) 
to give the desired product after lyophilization of the appropriate fractions. 
(2-((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-
ethyl) phosphonic acid (3a): Deprotection of compound 10a (0.13 g, 0.30 mmol) with TMSBr (0.91 g, 
5.95 mmol) according to the general procedure yielded compound 3a as a white power (32.2 mg, 
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29.1%). 1H-NMR (300 MHz, D2O) δ: 1.79–2.21 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 3.93–4.06 (m, 
1H, H-4'), 4.34 (t, J = 6.9 Hz, 1H, H-3'), 4.86 (dd, J = 6.2, 4.4 Hz, 1H, H-2'), 6.09 (d, J = 3.8 Hz, 1H, 
H-1'), 7.35 (t, J = 7.5 Hz, 1H, Ph), 7.48 (d, J = 8.5 Hz, 1H, Ph), 7.71–7.81 (m, 1H, Ph), 8.00 (d,  
J = 7.9 Hz, 1H, Ph). 13C-NMR (75 MHz, D2O) δ: 22.89 (d, J = 135.8 Hz, C-6'), 25.82 (d, J = 3.9 Hz, 
C-5'), 71.04 (C-2'), 72.22 (C-3'), 82.47 (d, J = 17.7 Hz, C-4'), 90.85 (C-1'), 115.11, 115.72, 124.53, 
128.05, 136.31 and 140.37 (Ph) 150.95 (C-2), 164.12 (C-4). 31P-NMR (D2O) δ: 29.02. HRMS (ESI): 
calculated for C14H16N2O8P [(M−H)−], 371.0650; found, 371.0651. 
(2-((2R,3S,4R,5R)-5-(6-fluoro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxytetrahydro-
furan-2-yl)ethyl)phosphonic acid (3b): The reaction between compound 10b (286.4 mg, 0.54 mmol) 
and TMSBr (1.65 g, 10.79 mmol) as described above, yielded compound 3b as a white powder  
(15.7 mg, 14.8%). 1H-NMR (300 MHz, DMSO-d6) δ:1.50–2.04 (m, 4H, H-5'a, H-5'b, H-6'a and  
H-6'b), 3.65–3.76 (m, 1H, H-4'), 4.04 (t, J = 6.7 Hz, 1H, H-3'), 4.49 (dd, J = 6.4, 4.7 Hz, 1H, H-2'), 
5.98 (d, J = 4.4 Hz, 1H, H-1'), 6.66 (br s, 4H, 4OH), 7.47–7.55 (m, 1H, Ph), 7.55–7.64 (m, 1H, Ph), 
7.71 (dd, J = 8.2, 2.9 Hz, 1H, Ph), 11.79 (br s, 1H, NH). 13C-NMR (75 MHz, DMSO-d6) δ: 23.81 (d,  
J = 137.3 Hz, C-6'), 26.41 (C-5'), 69.88 (C-2'), 72.11 (C-3'), 82.49 (d, J = 17.7 Hz, C-4'), 90.77 (C-1′'), 
112.63–113.19 (m, C-5), 117.91 (d, J = 7.7 Hz, C-4a), 118.12 (d, J = 7.7 Hz, C-8), 122.31–122.85 
(m, C-7), 136.87 (d, J = 1.7 Hz, C-8a), 149.73 (C-2), 156.06–159.37 (m, C-6), 160.85 (d, J = 2.2 Hz, 
C-4). 31P-NMR (CDCl3) δ: 26.92. HRMS (ESI): calculated for C14H15FN2O8P [(M−H)−], 389.0556; 
found, 389.0560. 
(2-((2R,3S,4R,5R)-5-(6-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)-3,4-dihydroxytetrahydro-
furan-2-yl)ethyl)phosphonic acid (3c): The reaction between compound 10c (0.14 g, 0.31 mmol) and 
TMSBr (0.94 g, 6.11mmol) as described above, yielded compound 3c as a white powder (49.0 mg, 
39.5%). 1H-NMR (300 MHz, D2O) δ:1.80–2.17 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 3.87–3.98 (m, 
1H, H-4'), 4.28 (t, J = 7.0 Hz, 1H, H-3'), 4.76 (d, J = 3.8 Hz, 1H, H-2'), 5.88 (d, J = 3.8 Hz, 1H, H-1'), 
7.25 (d, J = 9.4 Hz, 1H, Ph), 7.50 (dd, J = 9.1, 2.3 Hz, 1H, Ph), 7.56–7.61 (m, 1H, Ph). 13C-NMR  
(75 MHz, D2O) δ: 22.69 (d, J = 135.8 Hz, C-6'), 25.63 (d, J = 3.3 Hz, C-5'), 71.29 (C-2'), 72.21 (C-3'), 
82.29 (d, J = 18.3 Hz, C-4'), 90.98 (C-1'), 116.62, 116.96, 126.91, 129.32, 135.69 and 138.75 (Ph), 
150.20 (C-2), 162.11 (C-4). 31P-NMR (D2O) δ: 30.04. HRMS (ESI): calculated for [C14H15ClN2O8P 
[(M−H)−], 405.0260; found, 405.0266. 
(2-((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)tetrahydro-
furan-2-yl)ethyl)phosphonic acid (3d): The reaction between compound 10d (0.11 g, 0.25 mmol) and 
TMSBr (0.77 g, 5.01mmol) as described above, yielded compound 3d as a white powder (39.6 mg, 
41.0%). 1H-NMR (300 MHz, D2O) δ:1.82–2.13 (m, 4H, H-5'a, H-5′b, H-6'a and H-6'b), 2.20 (s, 3H, 
CH3), 3.86–3.97 (m, 1H, H-4'), 4.28 (t, J = 7.0 Hz, 1H, H-3'), 4.73 (m, 1H, H-2'), 5.86 (d, J = 3.2 Hz, 
1H, H-1'), 7.12 (d, J = 8.5 Hz, 1H, Ph), 7.31–7.44 (m, 2H, Ph). 13C-NMR (75 MHz, D2O) δ: 19.62 
(CH3), 22.76 (d, J = 133.5 Hz, C-6'), 25.66 (d, J = 2.8 Hz, C-5′), 71.32 (C-2'), 72.26 (C-3'), 82.13 (d,  
J = 17.7 Hz, C-4'), 90.82 (C-1′), 114.83, 114.96, 127.30, 134.51, 136.96 and 137.79 (Ph), 150.46 (C-2), 
163.38 (C-4). 31P-NMR (D2O) δ: 29.86. HRMS (ESI): calculated for C15H18N2O8P [(M−H)−], 385.0806; 
found, 385.0819. 
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(2-((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-methoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)tetrahydro-
furan-2-yl)ethyl)phosphonic acid (3e): The reaction between compound 10e (0.11 g, 0.23 mmol) and 
TMSBr (0.70 g, 4.58 mmol) as described above, yielded compound 3e as a white powder (48.9 mg, 
53.1%). 1H-NMR (300 MHz, D2O) δ:1.78–2.18 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b), 3.86 (s, 3H, 
CH3), 3.93–4.01 (m, 1H, H-4'), 4.32 (t, J = 6.8 Hz, H-3'), 4.84 (dd, J = 6.6, 4.2 Hz, 1H, H-2'), 6.04 (d, 
J = 4.0 Hz, 1H, H-1'), 7.29–7.35 (m, 1H, Ph), 7.37–7.43 (m, 2H, Ph). 13C-NMR (75 MHz, D2O)  
δ: 22.99 (d, J = 126.1 Hz, C-6'), 25.51 (C-5'), 55.90 (CH3), 70.98 (C-2'), 72.21 (C-3'), 82.46 (d,  
J = 18.2 Hz, C-4'), 90.83 (C-1'), 109.87, 116.65, 116.92, 123.80, 134.38 and 155.46 (Ph), 150.68 (C-2), 
163.60 (C-4). 31P-NMR (D2O) δ: 28.81. HRMS (ESI): calculated for C15H18N2O9P [(M−H)−], 
401.0755; found, 401.0755. 
(2-((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-3,4-dihydroxytetra- 
hydrofuran-2-yl)ethyl)phosphonic acid (3f): The reaction between compound 10f (0.18 g, 0.41 mmol) 
and TMSBr (1.24 g, 8.13 mmol) as described above, yielded compound 3f as a white powder (75.6 mg, 
49.2%). 1H-NMR (300 MHz, DMSO-d6) δ:1.48–2.04 (m, 4H, H-5'a, H-5'b, H-6'a and H-6'b),  
3.67–3.77 (m, 1H, H-4'), 4.01 (t, J = 6.4 Hz, 1H, H-3'), 4.41 (dd, J = 6.4, 5.3 Hz, 1H, H-2'), 5.91 (d,  
J = 5.0 Hz, 1H, H-1'), 6.53 (br s, 2H, 2OH), 7.25 (d, J = 5.6 Hz, 1H, H-6), 8.12 (d, J = 5.3 Hz, 1H,  
H-7), 11.62 (s, 1H, NH). 13C-NMR (75 MHz, DMSO-d6) δ: 23.78 (d, J = 135.8 Hz, C-6', 26.48 (C-5'), 
70.41 (C-2'), 71.94 (C-3'), 83.00 (d, J = 17.7 Hz, C-4'), 90.78 (C-1′), 113.85 (C-4a), 118.02 (C-6), 
135.77 (C-7), 145.17 (C-7a), 150.77 (C-2), 157.91 (C-4). 31P-NMR (DMSO-d6) δ: 28.07. HRMS 
(ESI): calculated for C12H14N2O8PS [(M−H)−], 377.0214; found, 377.0197. 
(2-((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydrobenzo[g]quinazolin-1(2H)-yl)-3,4-dihydroxytetrahydro-
furan-2-yl)ethyl)phosphonic acid (3g): The reaction between compound 10g (0.32 g, 0.56 mmol) and 
TMSBr (1.73 g, 11.30 mmol) as described above. The working up as follows: After stirring overnight, 
the reaction mixture was evaporated and co-distilled with toluene. The residue was dissolved with 7 N 
NH3/MeOH (10 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated 
and purified with RP high-performance liquid chromatography (HPLC, Phenomenex Luna C-18, 
H2O/0.1% HCOOH in CH3CN, 90:10→0:100 in 23 min, flow 17.5 mL/min) to give the compound 3g 
as a white power (50.0 mg, 21.0%). 1H-NMR (300 MHz, DMSO-d6) δ:1.52–2.14 (m, 4H, H-5'a, H-5'b, 
H-6'a and H-6'b), 3.75–3.85 (m, 1H, H-4'), 4.16 (t, J = 6.6 Hz, 1H, H-3'), 4.63 (dd, J = 6.4, 4.1 Hz, 
1H, H-2'), 5.21 (br s, 2H, 2OH), 6.10 (d, J = 4.1 Hz, 1H, H-1'), 7.49–7.58 (m, 1H, Ph), 7.61–7.70 (m, 
1H, Ph), 7.93 (s, 1H, Ph), 8.05 (d, J = 8.2 Hz, 1H, Ph), 8.13 (d, J = 8.2 Hz, 1H, Ph), 8.74 (s, 1H, Ph), 
11.67 (s, 1H, NH). 13C-NMR (75 MHz, DMSO-d6) δ: 23.54 (d, J = 137.1 Hz, C-6'), 26.14–26.32 (m, 
C-5'), 69.83 (C-2'), 71.82 (C-3'), 82.23 (d, J = 17.4 Hz, C-4'), 90.86 (C-1'), 111.25, 116.09, 125.56, 
127.35, 128.06, 128.75, 129.11, 129.22, 135.70 and 135.74 (Ph), 149.54 (C-2), 161.38 (C-4). 31P-NMR 
(DMSO-d6) δ: 26.39. HRMS (ESI): calculated for C18H18N2O9P [(M−H)−], 421.0806; found, 421.0795. 
3.4. Procedures for Phospholipase C assay 
Stable cell lines for study of the human (h) P2Y2, were generated by retroviral expression of the 
receptor in 1321N1 human astrocytoma cells, which do not natively express P2YRs. Agonist-induced 
[3H]inositol phosphate production was measured in cells plated at 20,000 cells/well on 96-well plates 
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two days prior to assay. Sixteen hours before the assay, the inositol lipid pool of the cells was 
radiolabeled by incubation in 100 μL of serum-free inositol-free Dulbecco’s modified Eagle’s medium, 
containing 1.0 μCi of [3H]myo-inositol. No changes of medium were made subsequent to the addition 
of [3H]inositol. On the day of the assay, cells were challenged with 25 μL of a five-fold concentrated 
solution of receptor agonists in 100 mM Hepes (N-(2-hydroxyethyl)-piperazine-N''-2-ethanesulfonic 
acid), pH 7.3 in HBSS, containing 50 mM LiCl for 30 min at 37 °C. Incubations were terminated by 
aspiration of the drug-containing medium and addition of 90 μL of ice-cold 50 mM formic acid. After 
30 min, supernatants were neutralized with 30 μL of 150 mM NH4OH and applied to Dowex AG1-X8 
anion exchange columns. Total inositol phosphates were eluted and radioactivity was measured using a 
liquid scintillation counter. Antagonist activities were conducted in a similar manner using a 
maximally efficatious dose of agonist with variable amount of antagonist.  
4. Conclusions  
Based on the earlier identification a 5-aryl-substituted uridine phosphonate analogue as a promising 
allosteric partial agonist of the P2Y2R, we prepared a small collection of a novel C5/C6-fused uridine 
phosphonates. Pharmacological evaluation revealed that the target compounds exhibit much weaker 
agonistic activity than the parent compound. 
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